TRIO 014 - version 3.0

• Research type

  Research Study

• Full title

  A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER, PHASE II STUDY OF ADDING AMG 479, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST INSULIN-LIKE GROWTH FACTOR TYPE 1 RECEPTOR (IGF-1R) TO FIRST LINE CHEMOTHERAPY IN PATIENTS WITH OPTIMALLY DEBULKED (LESS THAN 1 cm) EPITHELIAL OVARIAN CANCER

• IRAS ID

  52166

• Contact name

  Gordon Rustin

• Sponsor organisation

  Cancer International Research Group

• Eudract number

  2008-001551-22

• Clinicaltrials.gov Identifier

  NCT00718523

• Research summary

  This study will determine the value of adding AMG 479 to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (<1 cm) FIGO stage III and IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  10/H0711/88

• Date of REC Opinion

  19 Jan 2011

• REC opinion

  Further Information Favourable Opinion